WO2011089183A2 - Anticoagulant antidotes - Google Patents
Anticoagulant antidotes Download PDFInfo
- Publication number
- WO2011089183A2 WO2011089183A2 PCT/EP2011/050749 EP2011050749W WO2011089183A2 WO 2011089183 A2 WO2011089183 A2 WO 2011089183A2 EP 2011050749 W EP2011050749 W EP 2011050749W WO 2011089183 A2 WO2011089183 A2 WO 2011089183A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dabigatran
- seq
- antibody
- methyl
- group
- Prior art date
Links
- SJIOGTWFPQYLIF-UHFFFAOYSA-N CNc(c([NH+]([O-])[O-])c1)ccc1C(N(CCC(OC)=O)c1ccccc1)=O Chemical compound CNc(c([NH+]([O-])[O-])c1)ccc1C(N(CCC(OC)=O)c1ccccc1)=O SJIOGTWFPQYLIF-UHFFFAOYSA-N 0.000 description 1
- NKZRESTZFYZMSK-UHFFFAOYSA-N C[n]1c(ccc(C(N(CCC(NCCN)=O)c2ncccc2)=O)c2)c2nc1CNc(cc1)ccc1C(N)=N Chemical compound C[n]1c(ccc(C(N(CCC(NCCN)=O)c2ncccc2)=O)c2)c2nc1CNc(cc1)ccc1C(N)=N NKZRESTZFYZMSK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (32)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR112012018021-5A BR112012018021B1 (pt) | 2010-01-20 | 2011-01-20 | molécula de anticorpo capaz de neutralizar a atividade de dabigatrano e seu método de fabricação |
| MA35080A MA33936B1 (fr) | 2010-01-20 | 2011-01-20 | Antidotes pour anticoagulants |
| SG2012052445A SG182552A1 (en) | 2010-01-20 | 2011-01-20 | Anticoagulant antidotes |
| MEP-2017-29A ME02602B (me) | 2010-01-20 | 2011-01-20 | Antikoagulantni protivotrovi |
| EA201201016A EA028371B1 (ru) | 2010-01-20 | 2011-01-20 | Антидоты антикоагулянтов |
| AP2012006242A AP2012006242A0 (en) | 2010-01-20 | 2011-01-20 | Anticoagulant antidotes. |
| AU2011208719A AU2011208719C1 (en) | 2010-01-20 | 2011-01-20 | Anticoagulant antidotes |
| LTEP11703410.8T LT2525812T (lt) | 2010-01-20 | 2011-01-20 | Antikoaguliantų priešnuodžiai |
| CA2787566A CA2787566A1 (en) | 2010-01-20 | 2011-01-20 | Anticoagulant antidotes |
| NZ599508A NZ599508A (en) | 2010-01-20 | 2011-01-20 | Anticoagulant antidotes |
| MX2012008360A MX2012008360A (es) | 2010-01-20 | 2011-01-20 | Antidotos de anticoagulantes. |
| ES11703410.8T ES2614992T3 (es) | 2010-01-20 | 2011-01-20 | Antídotos de anticoagulantes |
| SI201131156A SI2525812T1 (sl) | 2010-01-20 | 2011-01-20 | Antikoagulantni antidoti |
| KR1020127019086A KR101781787B1 (ko) | 2010-01-20 | 2011-01-20 | 항응고제 해독제 |
| EP11703410.8A EP2525812B1 (en) | 2010-01-20 | 2011-01-20 | Anticoagulant antidotes |
| CN201180006616.4A CN102711813B (zh) | 2010-01-20 | 2011-01-20 | 抗凝血剂抗体 |
| RS20170195A RS55683B1 (sr) | 2010-01-20 | 2011-01-20 | Antikoagulantni protivotrovi |
| JP2012549355A JP5575923B2 (ja) | 2010-01-20 | 2011-01-20 | 抗凝固薬の解毒剤 |
| UAA201209779A UA110470C2 (ru) | 2010-01-20 | 2011-01-20 | Антидот антикоагулянта |
| DK11703410.8T DK2525812T3 (en) | 2010-01-20 | 2011-01-20 | Anticoagulant. |
| ZA2012/02876A ZA201202876B (en) | 2010-01-20 | 2012-04-19 | Anticoagulant antidotes |
| IL219427A IL219427B (en) | 2010-01-20 | 2012-04-25 | Anticoagulant antidotes |
| TNP2012000366A TN2012000366A1 (en) | 2010-01-20 | 2012-07-18 | Anticoagulant antidotes |
| HK13101025.2A HK1173957A1 (en) | 2010-01-20 | 2013-01-23 | Anticoagulant antidotes |
| CY20171100361T CY1118875T1 (el) | 2010-01-20 | 2017-03-22 | Αντιδοτα αντιπηκτικων |
| HRP20170613TT HRP20170613T1 (hr) | 2010-01-20 | 2017-04-14 | Antikoagulacijski protuotrovi |
| NL300882C NL300882I2 (nl) | 2010-01-20 | 2017-07-06 | idarucizumab |
| LTPA2017021C LTC2525812I2 (lt) | 2010-01-20 | 2017-07-10 | Antikoaguliantų priešnuodžiai |
| CY2017025C CY2017025I2 (el) | 2010-01-20 | 2017-07-10 | Αντιδοτα αντιπηκτικων |
| FR17C1026C FR17C1026I2 (fr) | 2010-01-20 | 2017-07-10 | Antidotes d'anticoagulants |
| NO2017034C NO2017034I1 (no) | 2010-01-20 | 2017-07-11 | Idarucizumab |
| LU00028C LUC00028I2 (ru) | 2010-01-20 | 2017-07-12 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10151239.0 | 2010-01-20 | ||
| EP10151239 | 2010-01-20 | ||
| US38391410P | 2010-09-17 | 2010-09-17 | |
| US61/383,914 | 2010-09-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2011089183A2 true WO2011089183A2 (en) | 2011-07-28 |
| WO2011089183A3 WO2011089183A3 (en) | 2011-11-17 |
Family
ID=42061991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2011/050749 WO2011089183A2 (en) | 2010-01-20 | 2011-01-20 | Anticoagulant antidotes |
Country Status (43)
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012098089A1 (en) * | 2011-01-19 | 2012-07-26 | Bayer Pharma Aktiengesellschaft | Binding proteins to inhibitors of coagulation factors |
| WO2012130834A1 (en) | 2011-03-30 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes |
| US8486398B2 (en) | 2010-01-20 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds |
| WO2015059159A1 (en) * | 2013-10-25 | 2015-04-30 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes |
| EP2980218A1 (en) * | 2014-07-30 | 2016-02-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors |
| US9522892B2 (en) | 2011-11-29 | 2016-12-20 | Perosphere Inc. | Anticoagulant reversal agents |
| US9593166B2 (en) | 2013-03-14 | 2017-03-14 | Bayer Healthcare Llc | Monoclonal antibodies against antithrombin β |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2865068T3 (es) | 2011-01-14 | 2021-10-14 | Univ California | Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos |
| TW201623331A (zh) * | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| CN105223348A (zh) * | 2014-05-26 | 2016-01-06 | 北京九强生物技术股份有限公司 | 人抗凝血酶iii的胶乳增强免疫比浊法检测试剂盒 |
| WO2016019145A1 (en) * | 2014-07-31 | 2016-02-04 | Haemonetics Corporation | Detection and classification of an anticoagulant using a clotting assay |
| WO2016044645A1 (en) * | 2014-09-17 | 2016-03-24 | Elmaleh David R | Anticoagulant derivatives for cardiovascular imaging |
| WO2016107605A1 (zh) | 2014-12-31 | 2016-07-07 | 昆明积大制药股份有限公司 | 药物组合物及其制备方法 |
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| IL275453B1 (en) * | 2017-12-24 | 2024-02-01 | Noile Immune Biotech Inc | An immunocompetent cell expressing a cell surface compound that specifically recognizes human mesothelin, IL-7, and CCL19 |
| US11873341B2 (en) | 2018-03-13 | 2024-01-16 | Tusk Therapeutics Ltd. | Anti-CD25 for tumour specific cell depletion |
| JP7407742B2 (ja) * | 2018-05-11 | 2024-01-04 | ハルシオン セラピューティクス インコーポレイテッド | Ｇａｓｐ－１顆粒を標的とする結合性タンパク質及びキメラ抗原受容体ｔ細胞並びにそれらの使用 |
| KR20210086682A (ko) | 2018-10-29 | 2021-07-08 | 화하이 유에스 인코퍼레이티드 | 신규한 디펩티드 화합물과 이의 용도 |
| WO2020180489A1 (en) | 2019-03-06 | 2020-09-10 | University Of Rochester | Anticoagulant compositions and uses thereof |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| TW202321311A (zh) * | 2021-08-02 | 2023-06-01 | 日商諾伊爾免疫生物科技股份有限公司 | 與scFv等之連接子結合的抗體 |
| US11446286B1 (en) * | 2022-02-28 | 2022-09-20 | King Faisal University | Treatment of fungal infections using dabigatran etexilate |
Citations (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| WO1991017271A1 (en) | 1990-05-01 | 1991-11-14 | Affymax Technologies N.V. | Recombinant library screening methods |
| WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
| WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| WO1994029348A2 (en) | 1993-06-03 | 1994-12-22 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| WO1998025971A1 (en) | 1996-12-10 | 1998-06-18 | Celltech Therapeutics Limited | Monovalent antibody fragments |
| WO1998037075A1 (de) | 1997-02-18 | 1998-08-27 | Boehringer Ingelheim Pharma Kg | Disubstituierte bicyclische heterocyclen, ihre herstellung und ihre verwendung als arzneimittel |
| US5817309A (en) | 1992-02-11 | 1998-10-06 | Max-Planck-Gesellschaft | Antidote for hirudin and synthetic thrombin inhibitors and method of use |
| WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US6060300A (en) | 1996-02-12 | 2000-05-09 | Basf Aktiengesellschaft | Thrombin muteins as antidotes for thrombin inhibitors |
| US6086871A (en) | 1995-06-13 | 2000-07-11 | Baxter Aktiengesellschaft | Prothrombin derivatives |
| US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
| WO2001079258A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2002056910A1 (en) | 2001-01-17 | 2002-07-25 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003050531A2 (en) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
| WO2004081026A2 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Polypeptides |
| WO2009042962A2 (en) | 2007-09-28 | 2009-04-02 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| KR100254759B1 (ko) * | 1992-01-23 | 2000-05-01 | 플레믹 크리스티안 | 단량체 및 이량체 항체-단편 융합 단백질 |
| DE19729544A1 (de) * | 1997-07-10 | 1999-01-14 | Basf Ag | Ancrod spezifische monoklonale Antikörper, Antikörperfragmente, deren Mischung oder Derivate und deren Verwendung |
| US6440417B1 (en) | 1998-11-06 | 2002-08-27 | Conjuchem, Inc. | Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20070031438A1 (en) * | 2001-12-10 | 2007-02-08 | Junghans Richard P | Antibodies as chimeric effector cell receptors against tumor antigens |
| AR070141A1 (es) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | Anticuerpos humanizados especificos para el factor von willebrand |
| ES2436076T3 (es) | 2009-08-24 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Intervenciones de urgencia de carbón vegetal activo con sobredosificación con etexilato de dabigatrán |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
-
2011
- 2011-01-19 AR ARP110100179A patent/AR079944A1/es active IP Right Grant
- 2011-01-19 TW TW100102006A patent/TWI513466B/zh active
- 2011-01-20 UY UY0001033196A patent/UY33196A/es active IP Right Grant
- 2011-01-20 MX MX2012008360A patent/MX2012008360A/es active IP Right Grant
- 2011-01-20 CN CN201180006616.4A patent/CN102711813B/zh active Active
- 2011-01-20 MA MA35080A patent/MA33936B1/fr unknown
- 2011-01-20 US US13/010,403 patent/US8486398B2/en active Active
- 2011-01-20 SG SG2012052445A patent/SG182552A1/en unknown
- 2011-01-20 SI SI201131156A patent/SI2525812T1/sl unknown
- 2011-01-20 EP EP11703410.8A patent/EP2525812B1/en active Active
- 2011-01-20 JP JP2012549355A patent/JP5575923B2/ja active Active
- 2011-01-20 GE GEAP201112836A patent/GEP20156341B/en unknown
- 2011-01-20 RS RS20170195A patent/RS55683B1/sr unknown
- 2011-01-20 PE PE2012000997A patent/PE20121516A1/es active IP Right Grant
- 2011-01-20 KR KR1020127019086A patent/KR101781787B1/ko active IP Right Grant
- 2011-01-20 BR BR112012018021-5A patent/BR112012018021B1/pt active IP Right Grant
- 2011-01-20 AP AP2012006242A patent/AP2012006242A0/xx unknown
- 2011-01-20 EP EP16205771.5A patent/EP3195876A1/en not_active Withdrawn
- 2011-01-20 ME MEP-2017-29A patent/ME02602B/me unknown
- 2011-01-20 CA CA2787566A patent/CA2787566A1/en not_active Abandoned
- 2011-01-20 AU AU2011208719A patent/AU2011208719C1/en active Active
- 2011-01-20 EA EA201201016A patent/EA028371B1/ru active Protection Beyond IP Right Term
- 2011-01-20 HU HUE11703410A patent/HUE032263T2/en unknown
- 2011-01-20 LT LTEP11703410.8T patent/LT2525812T/lt unknown
- 2011-01-20 PL PL11703410T patent/PL2525812T3/pl unknown
- 2011-01-20 WO PCT/EP2011/050749 patent/WO2011089183A2/en active Application Filing
- 2011-01-20 UA UAA201209779A patent/UA110470C2/ru unknown
- 2011-01-20 DK DK11703410.8T patent/DK2525812T3/en active
- 2011-01-20 MY MYPI2012002840A patent/MY162323A/en unknown
- 2011-01-20 NZ NZ599508A patent/NZ599508A/en unknown
- 2011-01-20 PT PT117034108T patent/PT2525812T/pt unknown
- 2011-01-20 ES ES11703410.8T patent/ES2614992T3/es active Active
-
2012
- 2012-04-19 ZA ZA2012/02876A patent/ZA201202876B/en unknown
- 2012-04-25 IL IL219427A patent/IL219427B/en active IP Right Grant
- 2012-07-18 TN TNP2012000366A patent/TN2012000366A1/en unknown
- 2012-07-23 CO CO12123109A patent/CO6571889A2/es active IP Right Grant
- 2012-08-14 EC ECSP12012105 patent/ECSP12012105A/es unknown
-
2013
- 2013-01-23 HK HK13101025.2A patent/HK1173957A1/xx unknown
- 2013-06-13 US US13/916,994 patent/US9034822B2/en active Active
-
2014
- 2014-07-02 JP JP2014136811A patent/JP2014210794A/ja active Pending
-
2015
- 2015-04-13 US US14/684,576 patent/US20150210778A1/en not_active Abandoned
-
2017
- 2017-03-22 CY CY20171100361T patent/CY1118875T1/el unknown
- 2017-04-14 HR HRP20170613TT patent/HRP20170613T1/hr unknown
- 2017-07-06 NL NL300882C patent/NL300882I2/nl unknown
- 2017-07-10 LT LTPA2017021C patent/LTC2525812I2/lt unknown
- 2017-07-10 FR FR17C1026C patent/FR17C1026I2/fr active Active
- 2017-07-10 CY CY2017025C patent/CY2017025I2/el unknown
- 2017-07-11 NO NO2017034C patent/NO2017034I1/no unknown
- 2017-07-12 LU LU00028C patent/LUC00028I2/fr unknown
- 2017-07-13 HU HUS1700030C patent/HUS1700030I1/hu unknown
-
2022
- 2022-08-12 NO NO2022036C patent/NO2022036I1/no unknown
Patent Citations (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| WO1991017271A1 (en) | 1990-05-01 | 1991-11-14 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5817309A (en) | 1992-02-11 | 1998-10-06 | Max-Planck-Gesellschaft | Antidote for hirudin and synthetic thrombin inhibitors and method of use |
| WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
| WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| WO1994029348A2 (en) | 1993-06-03 | 1994-12-22 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| US6086871A (en) | 1995-06-13 | 2000-07-11 | Baxter Aktiengesellschaft | Prothrombin derivatives |
| US6060300A (en) | 1996-02-12 | 2000-05-09 | Basf Aktiengesellschaft | Thrombin muteins as antidotes for thrombin inhibitors |
| US6200955B1 (en) | 1996-06-11 | 2001-03-13 | Commonwealth Biotechnologies, Inc. | Heparin binding peptides |
| WO1998025971A1 (en) | 1996-12-10 | 1998-06-18 | Celltech Therapeutics Limited | Monovalent antibody fragments |
| WO1998037075A1 (de) | 1997-02-18 | 1998-08-27 | Boehringer Ingelheim Pharma Kg | Disubstituierte bicyclische heterocyclen, ihre herstellung und ihre verwendung als arzneimittel |
| WO1998048837A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US6624141B1 (en) | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
| WO2001079258A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2002056910A1 (en) | 2001-01-17 | 2002-07-25 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003050531A2 (en) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
| WO2004081026A2 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Polypeptides |
| WO2009042962A2 (en) | 2007-09-28 | 2009-04-02 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
Non-Patent Citations (53)
| Title |
|---|
| BARBAS ET AL., PROC. NAT. ACAD. SCI, USA, vol. 91, 1994, pages 3809 - 3813 |
| BIJSTERVELD, NR ET AL., BRITISH J. OF HAEMATOLOGY, 2004, pages 653 - 658 |
| BIJSTERVELD, NR ET AL., CIRCULATION, vol. 106, 2002, pages 2550 - 2554 |
| BILLETTA R; LOBUGLIO AF.: "Chimeric antibodies", INT REV IMMUNOL., vol. 10, no. 2-3, 1993, pages 165 - 76 |
| BRUGGEMANN M; TAUSSIG MJ.: "Production of human antibody repertoires in transgenic mice", CURR OPIN BIOTECHNOL., vol. 8, no. 4, August 1997 (1997-08-01), pages 455 - 8 |
| BURTET ET AL., J. BIOCHEM., vol. 142, no. 6, 2007, pages 665 - 669 |
| CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
| CONNOLLY S ET AL., N ENGL J MED, vol. 361, no. 12, 2009, pages 1139 - 51 |
| CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085 |
| D. MARKS; H.R. HOOGENBOOM; T.P. BONNERT; J. MCCAFFERTY; A.D. GRIFFITHS; G. WINTER: "By-passing immunisation. Human antibodies from V-gene libraries displayed on phage", J.MOI.BIOL., vol. 222, 1991, pages 581 - 597 |
| DARLING, R.J.; BRAULT P-A.: "Kinetic exclusion assay technology: Characterization of Molecular Interactions", ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, vol. 2, no. 6, December 2004 (2004-12-01), pages 647 - 657 |
| DARLING, R.J.; BRAULT PA.: "Kinetic exclusion assay technology: Characterization of Molecular Interactions", ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, vol. 2, no. 6, December 2004 (2004-12-01), pages 647 - 657 |
| DELISA ET AL., BIOTECHNOLOGY AND BIOENGINEERING, vol. 65, no. 1, 1999, pages 54 - 64 |
| E.A. KABAT; T.T. WU; H. BILOFSKY; M. REID-MILLER; H. PERRY: "Sequence of Proteins of Immunological Interest", 1983, NATIONAL INSTITUTES OF HEALTH |
| EBNER ET AL., DRUG METAB. DISPOS., vol. 38, no. 9, 2010, pages 1567 - 75 |
| ERIKSSON ET AL., LANCET, vol. 370, no. 9591, 2007, pages 949 - 56 |
| H. BOUNAMEAUX; MARBET GA; LAMMLE B ET AL.: "Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behaviour of antithrombin III", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, vol. 74, no. 1, 1980, pages 68 - 72 |
| HAUEL ET AL., J MED CHEM, vol. 45, no. 9, 2002, pages 1757 - 66 |
| HEZAREH ET AL., JOURNAL OF VIROLOGY, vol. 75, 2001, pages 12161 - 12168 |
| HOLLIGER ET AL., PROC NATL ACAD SCI U S A., vol. 90, no. 14, 15 July 1993 (1993-07-15), pages 6444 - 8 |
| HUSTON ET AL., INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 10, 1993, pages 195 - 217 |
| KIPRIYANOW; LE GALL, MOLECULAR BIOTECHNOLOGY, vol. 26, 2004, pages 39 - 60 |
| KLEEMANN ET AL., ANAL. CHEM., vol. 80, 2008, pages 2001 - 2009 |
| KNAPPIK ET AL., J. MOL. BIOL., vol. 296, 2000, pages 57 - 86 |
| LAURITZEN, B. ET AL., BLOOD, 2005, pages 607A - 608A |
| LONBERG N; HUSZAR D.: "Human antibodies from transgenic mice", INT REV IMMUNOL., vol. 13, no. 1, 1995, pages 65 - 93, XP000944265 |
| MALMQVIST M.: "Surface plasmon resonance for detection and measurement of antibody-antigen affinity and kinetics", CURR OPIN IMMUNOL., vol. 5, no. 2, April 1993 (1993-04-01), pages 282 - 6, XP023942016, DOI: doi:10.1016/0952-7915(93)90019-O |
| MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779 - 783 |
| NATURE, vol. 256, 1975, pages 495 - 7 |
| NING ET AL., BIOCHEM. MOL. BIOL., vol. 38, 2005, pages 204 - 299 |
| NORDERHAUG ET AL., J IMMUNOL METHODS, vol. 204, no. 1, 1997, pages 77 - 87 |
| NORDERHAUG L; OLAFSEN T; MICHAELSEN TE; SANDLIE I.: "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells", J IMMUNOL METHODS, vol. 204, no. 1, May 1997 (1997-05-01), pages 77 - 87, XP004107719, DOI: doi:10.1016/S0022-1759(97)00034-3 |
| QUINTERO-HERNANDEZ ET AL., MOL. IMMUNOL., vol. 44, 2007, pages 1307 - 1315 |
| REVETS ET AL., EXPERT OPIN BIOL THER., vol. 5, no. 1, 2005, pages 111 - 24 |
| RIECHMANN L; CLARK M; WALDMANN H; WINTER G: "Reshaping human antibodies for therapy", NATURE, vol. 332, 1988, pages 323, XP000020414, DOI: doi:10.1038/332323a0 |
| RIPPMANN ET AL., APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 64, no. 12, 1998, pages 4862 - 4869 |
| S. CARMEN; L. JERMUTUS: "Concepts in antibody phage display", BRIEFINGS IN FUNCTIONAL GENOMICS AND PROTEOMICS, vol. 1, no. 2, 2002, pages 189 - 203, XP002664016, DOI: doi:10.1093/bfgp/1.2.189 |
| SCHULMAN S ET AL., N ENGL J MED, vol. 361, no. 24, 2009, pages 2342 - 52 |
| SCHULMAN; BIJSTERVELD, TRANSFUSION MEDICINE REVIEWS, vol. 21, no. 1, 2007, pages 37 - 48 |
| SHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155 |
| SHUKLA ET AL., J. CHROMATOGRAPHY B, vol. 848, no. 1, 2007, pages 28 - 39 |
| SKERRA, CURRENT OPINION IN BIOTECHNOLOGY, vol. 18, no. 4, 2007, pages 295 - 304 |
| SONODA ET AL., PROTEIN EXPR. PURIF., vol. 70, no. 2, 2010, pages 248 - 253 |
| SRINIVASAN; ROESKE, CURRENT PROTEIN PEPT. SCI., vol. 6, no. 2, 2005, pages 185 - 96 |
| STEINER ET AL., J MOL BIOL., vol. 382, no. 5, 24 October 2008 (2008-10-24), pages 1211 - 27 |
| STUMPP MT; AMSTUTZ P., CURR OPIN DRUG DISCOV DEVEL., vol. 10, no. 2, March 2007 (2007-03-01), pages 153 - 9 |
| URLAUB,G.; KAS,E.; CAROTHERS,A.M.; CHASIN,L.A.: "Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells", CELL, vol. 33, 1983, pages 405 - 412, XP027463007, DOI: doi:10.1016/0092-8674(83)90422-1 |
| WALLENTIN ET AL., LANCET, vol. 376, no. 9745, 2010, pages 975 - 983 |
| WARD ET AL., NATURE, vol. 341, no. 6242, 12 October 1989 (1989-10-12), pages 544 - 6 |
| WILLEMS ET AL., J. CHROMATOGR. B. ANALYT. TECHNOL. BIOMED. LIFE SCI., vol. 786, 2003, pages 161 - 176 |
| WILMS ET AL., BIOTECHNOLOGY AND BIOENGINEERING, vol. 73, no. 2, 2001, pages 95 - 103 |
| YAMAWAKI ET AL., J. BIOSCI. BIOENG., vol. 104, no. 5, 2007, pages 403 - 407 |
| ZIKRIA; ANSELL, CURRENT OPINION IN HEMATOLOGY, vol. 16, no. 5, 2009, pages 347 - 356 |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8486398B2 (en) | 2010-01-20 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds |
| US9034822B2 (en) | 2010-01-20 | 2015-05-19 | Boehringer Igelheim International Gmbh | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
| US20140050743A1 (en) * | 2011-01-19 | 2014-02-20 | Bayer Intellectual Property Gmbh | Binding proteins to inhibitors of coagulation factors |
| WO2012098089A1 (en) * | 2011-01-19 | 2012-07-26 | Bayer Pharma Aktiengesellschaft | Binding proteins to inhibitors of coagulation factors |
| WO2012130834A1 (en) | 2011-03-30 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes |
| CN103476459A (zh) * | 2011-03-30 | 2013-12-25 | 勃林格殷格翰国际有限公司 | 抗凝血剂解毒剂 |
| US8821871B2 (en) | 2011-03-30 | 2014-09-02 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof |
| US9522892B2 (en) | 2011-11-29 | 2016-12-20 | Perosphere Inc. | Anticoagulant reversal agents |
| US9877961B2 (en) | 2011-11-29 | 2018-01-30 | Perosphere Inc. | Anticoagulant reversal agents |
| US9593166B2 (en) | 2013-03-14 | 2017-03-14 | Bayer Healthcare Llc | Monoclonal antibodies against antithrombin β |
| US9908942B2 (en) | 2013-03-14 | 2018-03-06 | Bayer Healthcare, Llc | Monoclonal antibodies against antithrombin β |
| US10144784B2 (en) | 2013-03-14 | 2018-12-04 | Bayer Healthcare Llc | Monoclonal antibodies against antithrombin beta |
| US9499633B2 (en) | 2013-10-25 | 2016-11-22 | Boehringer Ingelheim International Gmbh | Dabigatran antidotes |
| WO2015059159A1 (en) * | 2013-10-25 | 2015-04-30 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes |
| WO2016016259A1 (en) * | 2014-07-30 | 2016-02-04 | Rheinische Friedrich-Wilhelms Universität Bonn | Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors |
| EP2980218A1 (en) * | 2014-07-30 | 2016-02-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011208719B2 (en) | Anticoagulant antidotes | |
| AU2011208719C1 (en) | Anticoagulant antidotes | |
| US8710192B2 (en) | PCSK9 antagonists | |
| JP2014511378A (ja) | Ｐｃｓｋ９アンタゴニスト | |
| US8821871B2 (en) | Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof | |
| US9499633B2 (en) | Dabigatran antidotes | |
| NZ613543B2 (en) | Anticoagulant antidotes | |
| AU2012234338A1 (en) | Anticoagulant antidotes | |
| OA16600A (en) | Anticoagulant antidotes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 201180006616.4 Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11703410 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011208719 Country of ref document: AU |
|
| ENP | Entry into the national phase |
Ref document number: 2011208719 Country of ref document: AU Date of ref document: 20110120 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 000997-2012 Country of ref document: PE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/008360 Country of ref document: MX |
|
| ENP | Entry into the national phase |
Ref document number: 2787566 Country of ref document: CA Ref document number: 20127019086 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2012549355 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REEP | Request for entry into the european phase |
Ref document number: 2011703410 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1201003589 Country of ref document: TH Ref document number: 6426/DELNP/2012 Country of ref document: IN Ref document number: 12012501493 Country of ref document: PH Ref document number: 2011703410 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12123109 Country of ref document: CO |
|
| WWE | Wipo information: entry into national phase |
Ref document number: A201209779 Country of ref document: UA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 201201016 Country of ref document: EA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 12836 Country of ref document: GE |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012018021 Country of ref document: BR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: P-2017/0195 Country of ref document: RS |
|
| ENP | Entry into the national phase |
Ref document number: 112012018021 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120719 |